Archives: 2019-08-25

A deluge of data: A pledge to the democratization of healthcare

AI and machine learning can transform data from health records — “real world data” — into “real world evidence” that will bolster the medical community’s collective knowledge exponentially. Yet, clinical decision support platforms are the only way all this added practice-based knowledge can actually be used to improve overall care. Since Stanford Medicine’s 2018 Health Trends

Read More


Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies

 Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia (CLI), welcomes the news announced today by Atelerix that it has been awarded a grant of £267,000 from Innovate UK. The grant will be used to develop gel stabilisation technologies, developed by Atelerix, with the first objective of extending the

Read More


Gene Editing in Patient-derived Heart Cells May Be Useful in FA

Removal of the genetic defect that causes Friedreich’s ataxia (FA) in heart cells derived from a patient with heart disease associated with FA reversed the cells’ abnormal molecular profile, a study shows. This gene-editing strategy could be a useful tool for regenerative medicine aimed at treating heart defects associated with the condition. The study, “Excision of the

Read More


New Articles in The CRISPR Journal

The CRISPR Journal announces the publication of its August 2019 issue. The Journal is dedicated to validating and publishing outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing, and commentary and debate of key policy, regulatory, and ethical issues affecting the field. The Journal, led by

Read More


New research published in cancer discovery identifies new drug target for glioblastoma

 A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells. While previous research has shown that a protein called

Read More